Inhibikase Therapeutics announces public offering of stock

Inhibikase Therapeutics Inc. (NASDAQ: IKT) announced it has commenced an underwritten public offering of common stock shares and pre-funded warrants. The clinical-stage pharmaceutical company developing treatments for pulmonary arterial hypertension said it will also grant underwriters a 30-day option to purchase up to an additional 15% of the total shares being offered.

The offering includes shares of common stock and pre-funded warrants to purchase common stock shares for certain investors. All securities in the proposed offering are being sold by the company itself.

Jefferies, BofA Securities and Cantor are serving as joint book-running managers for the offering. LifeSci Capital and Oppenheimer & Co. are acting as co-lead managers, while H.C. Wainwright & Co. and Ladenburg Thalmann & Co. Inc. are co-managers.

The securities are being offered under a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission and declared effective on June 27, 2025. The company stated that the offering is subject to market and other conditions, with no assurance regarding completion timing or final terms.

Inhibikase develops therapeutics targeting cardiopulmonary diseases, specifically pulmonary arterial hypertension, through inhibition of Abelson Tyrosine Kinase and type III receptor tyrosine kinases. The company's lead product candidate is IKT-001, a prodrug of imatinib mesylate for treating pulmonary arterial hypertension, which affects approximately 50,000 Americans.

The information is based on a company press release statement.

You May Also Be Interested In

• Accelevation prices IPO at $18 per share on Nasdaq
• Silexion Therapeutics exercises series E warrants for $837K
• Immix Biopharma prices $125M common stock offering at $11 per share